Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bill.com Holdings Inc (BILL) vs BioNTech SE - ADR (BNTX) Price & Performance

Bill.com Holdings IncTrade
BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

Bill.com Holdings Inc vs BioNTech SE - ADR — how do they compare? Bill.com Holdings Inc trades at $48.13 (market cap $4.93B), while BioNTech SE - ADR trades at $93.06 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 4.7× Bill.com Holdings Inc's market cap, and Bill.com Holdings Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BILLBNTX
Market Cap
$4.93B$23.31B
Sector
TechnologyHealth
52-Week High
$56.32$119.34
52-Week Low
$31.96$83.89
Enterprise Value
$4.64B$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bill.com Holdings Inc

BILL Holdings trades at $48.37, down 1.81% today, with a bullish technical signal and strong analyst support (56% buy ratings). The company shows improving fundamentals with revenue growth to $1.46B in 2025 and three consecutive quarterly EPS beats, though profitability remains thin with a net margin of 0.01%. Recent news highlights AI-driven strategy and operational efficiency gains.

Outlook is cautiously optimistic given earnings momentum and institutional accumulation, but high valuation (P/E 213.91) and negative cash flow from investing pose risks. Upside to consensus price target $45.67 appears limited at current levels, requiring sustained execution for further gains.

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bill.com Holdings Inc

Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.

Read more on BILL

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX